Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04484272 · ClinicalTrials.gov registry record · NA
A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease
A NA study of Sickle Cell Disease, sponsored by University of Florida.
- Recruiting
- Registry status
- NA
- Development phase
- 185
- Enrollment target
- 1
- Study location
NCT04484272: Recruiting NA study of Sickle Cell Disease, sponsored by University of Florida.
NCT04484272 is a NA study of Sickle Cell Disease that is actively recruiting participants, run by University of Florida. The registered enrollment target is 185 participants, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (37% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04484272, a NA study of Sickle Cell Disease, is actively recruiting participants, sponsored by University of Florida.
- RECRUITING
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
- 1
- Study location
Study Summary
Our long-term goal is to reduce stress and improve sickle cell disease (SCD) pain control with less opioid use through an intervention with self-management relaxation/distraction exercises (RDE), named You Cope, We Support (YCWS). Americans living with SCD suffer recurrent episodes of acute and chronic pain, both of which are exacerbated by stress. Building on the successes of our prior formative studies, we now propose a well-designed, appropriately powered study to test efficacy of YCWS on outcomes (pain intensity, stress intensity, opioid use) in adults with SCD. We propose to recruit 170 adults for a randomized controlled trial of the short-term (8 weeks) and long-term (6 months) effects of YCWS on outcomes (pain, stress, and opioid use). Stratified on worst pain intensity (\<=5; \>5), we will randomly assign patients to groups: 85 to Control (Self-monitoring of outcomes + alerts/reminders), and 85 to Experimental (Self-monitoring of outcomes + alerts/reminders + use of YCWS \[RDE + Support\]). We will ask participants to report outcomes daily. During weeks 1-8, we will send system-generated alerts/reminders to both groups via phone call, text, or email to facilitate data entry (both groups) and intervention use support (experimental). If the patient does not enter data after 24 hours, study support staff will contact him/her for data entry trouble-shooting (both groups) and YCWS use (experimental). We will time stamp and track participants' online activities to understand the study context and conduct exit interviews on acceptability of the staff and system-generated support. We will analyze data using mixed-effects regression models (short-term, long-term) to account for repeated measurements over time and utilize machine learning to construct and evaluate models predictive of outcomes. Specific aims are: Aim 1: To determine the short-term effects of YCWS. Aim 2: To determine the long-term effects of YCWS. Aim 3 (exploratory): Using machine learning, to develo
Primary Outcome
This 3-item scale asks patients to report their current, least, and worst stress intensity in the past 24 hours, on a scale of 0 (no stress) to 10 (stress as bad as it could be)
Conditions Studied
Interventions
- BEHAVIORAL Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]).
- BEHAVIORAL Self-monitoring of pain, stress, and opioid use + alerts/reminders.
Study Locations (1)
Florida
- University of Florida - Gainesville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2021-04-29 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT04484272 shows while recruiting
NCT04484272 is an interventional study that assigns participants to a tested intervention. The registered 185 participants enrollment target is mid-sized for trials with a published cap, below the 292-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (37% lower).
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]). is the first listed.
NCT04484272 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT04484272 about?
NCT04484272 is a clinical study titled "A Stress and Pain Self-management m-Health App for Adult Outpatients With Sickle Cell Disease". Our long-term goal is to reduce stress and improve sickle cell disease (SCD) pain control with less opioid use through an intervention with self-management relaxation/distraction exercises (RDE), named You Cope, We Support (YCWS). Americans living with SCD suffer recurrent episodes of acute and chro...
What is the current status of trial NCT04484272?
This trial is currently recruiting. It is a NA study. The enrollment target is 185 participants. The study started on 2021-04-29. Estimated completion is 2026-06-30.
What conditions does trial NCT04484272 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT04484272?
The interventions under investigation include: Self-monitoring of pain, stress, and opioid use + alerts/reminders + use of YCWS. [three video banks of RDE + Support]). (BEHAVIORAL), Self-monitoring of pain, stress, and opioid use + alerts/reminders. (BEHAVIORAL).
Who is sponsoring clinical trial NCT04484272?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04484272 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04484272's enrollment target sits among peer trials
185 39th of 213 higher than 175 of 213 other Sickle Cell Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Sickle Cell Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Life Exposures Among Children With Sickle Cell Disease
RECRUITING · NA
-
Exercise in Child Health
RECRUITING · NA
-
Sickle Cell Children's Exercise Study (SuCCESs)
RECRUITING · NA
-
Cutaneous Hydration Assessment in SCD
RECRUITING · NA
-
MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
RECRUITING · NA
-
Peer Support for Adolescents and Emerging Adults With Sickle Cell Pain
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041154 · 185 participants · NA
Behavioral and Neural Representations of Subjective Effort Cost
- NCT05020860 · 185 participants · Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
- NCT05793541 · 185 participants · NA
Just-in-time Interventions for Reducing Short-term Suicide Risk
- NCT05897424 · 185 participants · Phase 2
Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI